Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

Departament de Medicina

Conjunt de dades

1 Article

1 resultats

Filtre

2021
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
CETLAM group, 14 de gen. 2021, In: Clinical Epigenetics. 13, 1, 9.
Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

Accés Obert
24 Cites (Scopus)